Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

Biobanking 130

Biobanking Genetics Genome Project Genome 130

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Partnerships and Establishing Research Cohorts.

Research 98

Research Biobanking Drugs Genome 98

Pharmaceutical Technology

AUGUST 11, 2022

Using data from the UK Biobank database, genomic sequencing data for 360,000 individuals were obtained and the findings were confirmed in animal models that demonstrated a higher expression of the INHBE gene in obese monkeys when compared to more lean monkeys.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

pharmaphorum

MARCH 19, 2021

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? , According to an article by Stephens, Zachary D.,

Bioinformatics 59

Bioinformatics Drugs Genome Genomics 59

The Pharma Data

MARCH 1, 2022

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd. More information at www.lifebit.ai.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

Trialfacts

SEPTEMBER 12, 2024

Must not have a history of alcohol or drug abuse within the past 2 years. Must not have been diagnosed with cancer within the past 5 years, excluding completely treated in situ carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin or melanoma in situ.

Research 52

Research Gene Editing Biobanking Bioinformatics 52